Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc.

May 18, 2016 17:44 ET

Fennec Announces Upcoming Events and Presentations

RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - May 18, 2016) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF) (the "Company" or "Fennec"), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric patients, announced today upcoming events and presentations:

ASCO 2016 STS will be featured in an oral presentation titled "Two year results of clinical efficacy of cisplatin in combination with sodium thiosulfate (STS) vs cisplatin alone in a randomized phase III trial for standard risk hepatoblastoma (SR-HB)." at the 2016 American Society of Clinical Oncology (ASCO) meeting being held June 3 through June 7, 2016 in Chicago, IL. The oral presentation will be held on June 5, 2016 during the Pediatric Oncology II session. The abstract (Abstract #10514) is scheduled to be made available today on the website http://www.abstract.asco.org/.

Annual Meeting of Shareholders – Fennec would like to invite all shareholders to attend its Annual General and Special Meeting on Wednesday, June 8, 2016 at 10 am at the Langham Hotel in the Grant Room, 250 Franklin Street, Boston, Massachusetts.

Jefferies 2016 Global Healthcare Conference Rosty Raykov, CEO of Fennec, will provide an overview of the Company's business on Friday, June 10, 2016 at 2:30 p.m. (ET) at the Jefferies 2016 Global Healthcare Conference being held in New York City. The Fennec presentation will be webcast live and can be accessed by visiting the investors relations sections of the Company's website at http://fennecpharma.com/investors/presentations-events/. A replay of the presentation will also be available and archived on the site for ninety days.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric patients. STS has received Orphan Drug Designation in the US in this setting. For more information, please visit www.fennecpharma.com.

Forward-Looking Statement Disclaimer

Except for historical information described in this press release, all other statements are forward-looking, including statements or assumptions about regulatory approvals, anticipated use of proceeds and any other statements regarding the Company's objectives (and strategies to achieve such objectives), future expectations, beliefs, goals or prospects. Forward-looking statements are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including that regulatory and guideline developments may change; that scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals; that clinical results may not be replicated in actual patient settings; that protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors; that the available market for the Company's products will not be as large as expected; that the Company's products will not be able to penetrate one or more targeted markets; that revenues will not be sufficient to fund further development and clinical studies; that the Company may not meet its future capital requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2015. Fennec Pharmaceuticals Inc. disclaims any obligation to update these forward-looking statements except as required by law.

For a more detailed discussion of related risk factors, please refer to our public filings available at www.sec.gov and www.sedar.com.

Contact Information